drugset / Trial / NCT00238251

Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases

NCT00238251

Phase 2 Completed 59 enrolled Swiss Cancer Institute
RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with either gefitinib or temozolomide may kill more tumor cells. PURPOSE: This randomized phase II trial is studying how well giving radiation therapy together with either gefitinib or temozolomide works in treating patients with non-small cell lung cancer and brain metastases.

Timeline

Start
2005-05
Primary completion
2009-04
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gefitinib Small molecule 250 mg Oral
Comparator Temozolomide Small molecule 75 mg/m2 Oral